Navidea Biopharmaceuticals Inc.
NAVB wurde am 5. Oktober 2023 von der Börse genommen.
Profil: Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Mitarbeiter: 15
Nachrichten
Für NAVB liegen uns keine aktuellen Nachrichtenartikel vor.